Prospective Cohort of HIV/HBV-coinfected Patients in Europe
Euro-B
Understanding Treatment Outcomes of HIV/HBV Coinfection: A Prospective Cohort of HIV/HBV-coinfected Patients in Europe
2 other identifiers
observational
1,107
0 countries
N/A
Brief Summary
The overall aim of the project is to establish an international multi-cohort research platform of HIV/HBV-coinfected individuals treated with tenofovir to improve our understanding of the determinants of treatment outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2001
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 2, 2001
CompletedFirst Submitted
Initial submission to the registry
June 30, 2021
CompletedFirst Posted
Study publicly available on registry
August 2, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
December 1, 2023
November 1, 2023
29.3 years
June 30, 2021
November 30, 2023
Conditions
Outcome Measures
Primary Outcomes (6)
HBV suppression
Proportion of participants achieving undetectable HBV DNA
2 years of TDF/TAF-containing treatment and last available timepoint
HBsAg loss
Proportion of participants with a negative HBsAg measurement
2 years of TDF/TAF-containing treatment and last available timepoint
HBeAg loss
Proportion of participants with a negative HBeAg measurement
2 years of TDF/TAF-containing treatment and last available timepoint
Transaminase normalization
Proportion of participants with transaminase normalization
2 years of TDF/TAF-containing treatment and last available timepoint
Liver fibrosis change
Proportion of participants with a change in liver fibrosis stage
2 years of TDF/TAF-containing treatment and last available timepoint
Treatment interruption or change
Assessments of rates and reasons for treatment interruptions or changes
2 years of TDF/TAF-containing treatment and last available timepoint
Eligibility Criteria
HIV/HBV-coinfected individuals treated with tenofovir from Europe
You may qualify if:
- Study participant from contributing cohort
- positive HBsAg tests more than 6 months apart
- At least 2 data points (baseline and 2 years after TDF/TAF start either as available data or stored sample
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Begre L, Boyd A, Plissonnier ML, Testoni B, Beguelin C, Suter-Riniker F, Scholtes C, Rockstroh JK, Lacombe K, Peters L, Heil M, Levrero M, Rauch A, Zoulim F, Wandeler G; Swiss HIV Cohort Study, EuroSIDA and French HIV/HBV and Biliver cohorts; Members of the EuroSIDA Study Group; Members of the French HIV/HBV and Biliver cohorts. Circulating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe. JHEP Rep. 2025 Nov 7;8(2):101671. doi: 10.1016/j.jhepr.2025.101671. eCollection 2026 Feb.
PMID: 41551412DERIVED
Biospecimen
Plasma/serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Gilles Wandeler, MD MSc
Insel Gruppe AG, University Hospital Bern
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 30, 2021
First Posted
August 2, 2021
Study Start
October 2, 2001
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Last Updated
December 1, 2023
Record last verified: 2023-11